E-mail this Article (login required)
E-mail the Author (login required)
Post a Comment (login required)
VIEW COMPLETE HTML
VIEW COMPLETE PDF
Two Faces of the Same Coin: A Case Report of Antiphospholipid Syndrome Nephropathy
Sofia Homem de Melo Marques, Hugo André Nascimiento Ferreira, Ana Teresa Pires de Morais Nunes, Roberto Nicolau Pestana Silva, Susana Maria Moreira Sampaio Norton
http://dx.doi.org/10.12890/2017_000542
European Journal of Case Reports in Internal Medicine - © EFIM

ABSTRACT

Antiphospholipid syndrome (APS) is an autoimmune disease which can be primary or secondary to other autoimmune conditions and is defined by the occurrence of arterial or venous thrombosis, or pregnancy morbidity associated with persistently positive antiphospholipid antibodies (aPLA). The kidney may be affected by thrombosis at any level of its vasculature. When small vessels are involved, this results in thrombotic microangiopathy (TMA), which can manifest as either acute vaso-occlusive or chronic vascular lesions in glomeruli, arterioles and interlobular arteries. We report the case of 26-year-old man, with a previous medical history suggestive of APS, who was found to have a small elevation in serum creatinine. A kidney biopsy was performed and revealed features of chronic TMA. Anticoagulation was begun and kidney function remained stable. However, one year later, upon suspension of anticoagulation, the patient developed acute kidney injury and a second kidney biopsy showed acute TMA. This case describes different manifestations of antiphospholipid syndrome nephropathy (APSN) and highlights the importance of anticoagulation for thrombosis prevention.

KEYWORDS

Antiphospholipid syndrome, Antiphospholipid syndrome nephropathy, kidney biopsy, thrombotic microangiopathy

References
  1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306.
  2. Cervera R, Serrano R, Pons-Estel GJ, Ceberio-Hualde L, Shoenfeld Y, de Ramón E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis 2015;74:1011–1018.
  3. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012;157:47–58.


© EFIM Copyright 2016